PET市場

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Part of that medical imaging improvement is coming from positron emission tomography (PET). PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning. This sector includes all of the generally accepted imaging activities that are currently used in PET, including equipment for PET, PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines these clinical measurement devices and their reagents and supplies as used in hospitals and clinics. It also reviews associated clinical market segments in which PET scanning has taken a prominent role including cancer treatment, cardiology, and neurology imaging markets.

1. Overview

• 1.1 Statement of Report
• 1.2 Scope of this Report
• 1.3 Methodology
• 1.4 Executive Summary

2. Overview of the Medical Imaging Market

• 2.1 Medical Imaging Industry Market Size
• 2.2 Medical Imaging Infrastructure
  • 2.2.1 Total Healthcare Expenditures and Demographics
  • 2.2.2 Number of Hospitals
  • 2.2.3 Number of Radiologists
  • 2.2.4 Radiologic Services
  • 2.2.5 Medical Imaging Companies
  • 2.2.6 Medical Imaging Market Drivers
  • 2.2.7 Market Restraints
  • 2.2.8 Market Segments for PET Imaging
  • 2.2.9 Key Players in the PET Imaging Segment
  • 2.2.10 Medical Imaging Sector Analysis
• 2.3 Structure and Use of PET Imaging
  • 2.3.1 Functional Imaging versus Anatomic Imaging
  • 2.3.2 Functional Imaging Using Single-Photon Imaging (SPECT)
  • 2.3.3 PET in Clinical Use
  • 2.3.4 PET Sensitivity
  • 2.3.5 Therapeutic Uses of PET
  • 2.3.6 PET/CT
  • 2.3.7 The Future of PET in Cancer Imaging
  • 2.3.8 PET Reimbursement
• 2.4 Radiopharmaceutical Imaging
  • 2.4.1 Cardinal Health Acquires PET Radiopharmaceutical Production Facilities
  • 2.4.2 GE Healthcare Launches New Platform for Automated Synthesis of PET Radiopharmaceuticals
  • 2.4.3 Siemens Medical PETNET Radiopharmacy
  • 2.4.4 Future Growth of PET Imaging Procedures
  • 2.4.5 Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects
  • 2.4.6 New Radiopharmaceutical Applications

3. PET Market

• 3.1 Market Size
• 3.2 Total PET and PET/CT Market Trends
  • 3.2.1 Market Segmentation and Definitions
  • 3.2.2 Overview
  • 3.2.3 Market Measurements
  • 3.2.4 Market Drivers
  • 3.2.5 Market Restraints
  • 3.2.6 Future Needs for Market Development
  • 3.2.7 Clinical Usages
• 3.3 Total PET and PET/CT Market Forecasts
  • 3.3.1 Revenue Forecasts
  • 3.3.2 Unit Shipment Forecasts
  • 3.3.3 Procedure Forecast
  • 3.3.4 Competitive Structure
  • 3.3.5 Market Share Analysis
  • 3.3.6 Future Directions for PET
  • 3.3.7 New PET Technology Platforms
• 3.4 SPECT Market Forecasts
• 3.5 Stand-Alone PET Market Forecasts
  • 3.5.1 Revenue Forecasts
  • 3.5.2 Unit Shipment Forecasts
  • 3.5.3 Market Share Analysis
• 3.6 PET/CT Market Forecasts
  • 3.6.1 PET/CT Revenue Forecasts
  • 3.6.2 PET/CT Unit Shipment Forecasts
  • 3.6.3 PET/CT Market Share Analysis
• 3.7 Products
  • 3.7.1 Gamma Medica
  • 3.7.2 Mallinckrodt
  • 3.7.3 Naviscan PET Systems
  • 3.7.4 Siemens Medical
  • 3.7.5 TeraRecon
  • 3.7.6 Toshiba America Medical Systems
  • 3.7.7 CTI Molecular Imaging Inc.
  • 3.7.8 GE Healthcare
  • 3.7.9 Philips Medical Systems
  • 3.7.10 MedImage Inc.

4. PET/CT

• 4.1 Strengths of CT and PET Scanning
• 4.2 Combining CT' s Strengths with PET Scanning
• 4.3 Nuclear Medicine Safety Protocols
• 4.4 PET Safety Protocols
  • 4.4.1 Radiation Safety
  • 4.4.2 Appropriate Shielding
  • 4.4.3 Radioactive Package Protocols
• 4.5 Regulatory Requirements
• 4.6 PET and SPECT Tracers
  • 4.6.1 FDG Centers
• 4.7 PET Imaging
• 4.8 PET and Cancer Staging
• 4.9 PET/CT Reimbursement

5. Hybrid Technology: PET/CT and SPECT/CT

• 5.1 PET/CT
• 5.2 SPECT/CT
• 5.2.1 Blending of Technology Platforms
• 5.2.2 SPECT vs. PET

6. SPECT and SPECT/CT

• 6.1 Single-Photon Emission Computed Tomography (SPECT)
  • 6.1.1 SPECT Imaging
• 6.2 SPECT/CT
• 6.3 Potential Applications of SPECT/CT
• 6.4 New Technology Platforms: SPECT

7. Clinical PET/CT for Oncology Applications

• 7.1 Pulmonary Nodules
• 7.2 Non-Small-Cell Lung Cancer
• 7.3 Melanoma
• 7.4 Lymphoma
• 7.5 Colorectal Cancer
• 7.6 Head and Neck Cancer
• 7.7 Esophageal Cancer
• 7.8 Breast Cancer
• 7.9 Brain Cancer
• 7.10 Prostate Cancer
• 7.11 Ovarian Cancer
• 7.12 Cervical Cancer
• 7.13 Testicular Cancer
• 7.14 Thyroid Cancer
• 7.15 Pancreatic Cancer
• 7.16 Trends in Clinical Use of PET/CT
• 7.17 Development of PET/MRI

8. Company Listings

Appendix 1. Radiopharmaceutical Diagnostic Imaging Agent Codes and PET Scan Services

• Table 2.1: U.S. Medical Imaging Market Size, 2001 to 2010
• Table 2.2: Global Medical Imaging Market Size, 2001 to 2010
• Table 2.3: U.S. Healthcare Expenditures, 1999 to 2010
• Table 2.4: U.S. Health Expenditures as a Percentage of GDP, 1999 to 2010
• Table 2.5: U.S. User Expenditures for Medical Imaging Equipment and Related Products
• Table 3.1: Type of Imaging Offered by Facility
• Table 3.2: PET Procedures by Type
• Table 3.3: PET Patient Studies Performed in U.S.
• Table 3.4: Worldwide Dollar Sales of PET Imaging Systems, 2004 to 2011
• Table 3.5: U.S. Dollar Sales of PET Imaging Systems, 2004 to 2011
• Table 3.6: Average Selling Price for PET, U.S. and Worldwide, 2004 to 2011
• Table 3.7: Unit Sales of PET Imaging Systems, U.S. and Worldwide, 2004 to 2011
• Table 3.8: Installed Base of PET Imaging Systems, U.S., 2004 to 2011
• Table 3.9: PET Procedure Volume, 2004 to 2011
• Table 3.10: FDG Sales, 2004 to 2011
• Table 3.11: SPECT Procedure Volume, 2004 to 2011
• Table 3.12: U.S. SPECT Scanner Market Size and Growth, 2002 to 2010
• Table 3.13: U.S. Stand-Alone PET Scanner Market Size and Growth, 2004 to 2011
• Table 3.14: U.S. PET/CT Scanner Market Size and Growth, 2002 to 2010
• Table 4.1: PET Applications Approved for Reimbursement by CMS
• Table 5.1: SPECT and PET Hybrid Sales Percentages

ご注意：当報告書はDRM（デジタル著作権管理システム）付PDFとなります。ご購入頂いた場合、専用のビューアー（ご購入時無償配布）をPCにインストールして頂き、そのビューアーによってのみPDFの閲覧が可能となります。ファイルのコピー及び内容の抽出は出来ませんのでご注意下さい。尚、プリントアウトは何回でも可能です。ご不明な点につきましてはお問合せください。